



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	214424	MediHerb Horsechestnut Complex
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Integria Healthcare Australia Pty Ltd	
<b>Postal Address</b>	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
<b>ARTG Start Date</b>	11/09/2013	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27) as in force or existing from time to time. This condition does not apply to powdered or dried leaf.

### Products

#### 1 . MediHerb Horsechestnut Complex

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	10/03/2021
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support healthy blood circulation  
Maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet)  
Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of haemorrhoids  
Traditionally used in Western herbal medicine to decrease/reduce/relieve discomfort associated with haemorrhoids  
Traditionally used in Western herbal medicine to decrease/reduce/relieve itching associated with haemorrhoids  
Traditionally used in Western herbal medicine to decrease/reduce/relieve swelling associated with haemorrhoids  
Decrease/reduce/relieve symptoms of mild varicose veins  
Linked indication - Decrease/reduce/relieve pain associated with mild varicose veins  
Linked indication - Decrease/reduce/relieve aching/tired legs/leg heaviness associated with mild varicose veins  
Linked indication - Decrease/reduce/relieve itchy legs associated with mild varicose veins  
Linked indication - Decrease/reduce/relieve leg swelling associated mild varicose veins

#### Indication Requirements

Label statement: If symptoms persist, talk to your health professional.  
Product presentation must only refer to mild varicose veins.  
Product presentation must not imply or refer to serious cardiovascular conditions.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

If symptoms persist consult your healthcare practitioner (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form**                      Tablet, enteric coated

**Route of Administration**        Oral

**Visual Identification**

**Active Ingredients**

<b>Aesculus hippocastanum seed Extract dry concentrate standardised</b>	<b>200 mg</b>
Equivalent: Aesculus hippocastanum (Dry)	1200 mg
<b>Ginkgo biloba leaf Dry</b>	<b>30.5 mg</b>
Equivalent: Ginkgo biloba (Dry)	1525 mg
<b>Ruscus aculeatus root and rhizome Extract dry concentrate standardised</b>	<b>200 mg</b>
Equivalent: Ruscus aculeatus (Extract dry concentrate standardised)	800 mg

**Other Ingredients (Excipients)**

calcium hydrogen phosphate dihydrate  
carmellose sodium  
colloidal anhydrous silica  
ethylcellulose  
liquid glucose  
magnesium stearate  
maltodextrin  
medium chain triglycerides  
microcrystalline cellulose  
oleic acid  
polydextrose  
purified talc  
purified water  
sodium starch glycollate  
strong ammonia solution

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary